CMRX
$2.50
Chimerix
$.01
.40%
CMRX
Earnings Whisper ®
N/A
3rd Quarter September 2020
Consensus:  ($0.17)
Revenue:  $1.40 Mil
Monday
Nov 9
7:00 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when CMRX reports earnings?
Beat
Meet
Miss

Where is CMRX's stock price going from here?
Up
Flat
Down
Stock chart of CMRX
Analysts
Summary of analysts' recommendations for CMRX
Score
Grade
Pivots
Resistance
$2.69
$2.64
$2.57

$2.52

Support
$2.45
$2.40
$2.33
Tweet
Growth
Description
Chimerix, Inc. engages in the discovery, development and commercialization of oral antiviral therapeutics for various medical needs. The Company is developing various product candidates for the treatment of dsDNA viruses, HIV, hepatitis C, influenza and smallpox which are under different phases of clinical development. It is also screening our proprietary Chimerix Chemical Library for compounds with activity against dengue virus, malaria and tuberculosis. Chimerix, Inc. is headquartered in Durham, North Carolina.
Peers
InterCeptBioMarin PharmaceuticalRegeneron PharmaceuticalsVertex PharmaceuticalsZoetisJohnson & JohnsonMerck & Co.Ultragenyx PharmaceuticalBristol-Myers SquibbCatalent